836 Results
Sort By:
Published on August 27, 2019
Researchers at Institute for Systems Biology (ISB) have developed a method using using single-cell analysis to measure metabolic activities in rare disseminated tumor cells taken from non-small cell lung cancer (NSCLC) patients that can accurately predict how patients will respond to various cancer therapies, and how treatments will impact a…
Published on August 5, 2019
Genomind said today it will launch an enhanced version of its mental health genetic test that will feature a new, more focused report and set of services, all designed to help clinicians better understand a patient’s genetic profile and its implications for mental health treatment. Genomind Professional PGx Express, set…
Published on August 5, 2019
Liquid biopsy is just as good as traditional tumor testing at identifying microsatellite instability (MSI), an important biomarker used to predict response to immunotherapy regardless of tumor type. That’s according to a validation study that included nearly 1,000 patients. Researchers incorporated pan-cancer MSI detection into the 74-gene panel Guardant 360…
Published on August 2, 2019
Advanced Biological Laboratories (ABL) plans to launch a portable and affordable test for tuberculosis (TB) designed by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, the partners said, through an expanded licensing agreement whose value was not disclosed. Luxembourg-based ABL will manufacture, market, and distribute the…
Published on July 30, 2019
Illumina acknowledged delivering disappointing results during the second quarter, reporting a 42% year-over-year increase in net income that largely reflected an investment gain, and only a 1% year-over-year increase in quarterly revenues. GAAP net income during Q2 was $296 million, up from $209 million in the second three months of…
Published on July 29, 2019
Researchers studying nearly 147,000 veterans diagnosed with PTSD found that the disorder’s most characteristic symptom—re-experiencing—is associated with eight separate regions of the genome in whites. It is one of the largest genome-wide association studies (GWAS) of its kind to date. “Post-traumatic stress disorder (PTSD) is a major problem among military…
Published on July 24, 2019
Personal genomics company Helix is partnering with the Central Florida Division of healthcare provider AdventHealth in an ambitious study that will screen participants for four genes linked to familial hypercholesterolemia (FH). The study, titled WholeMe, will give 10,000 participants the opportunity to have Helix screen for pathogenic variants in the…
Published on July 22, 2019
Investigators from the Tufts University and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, have just uncovered that a rare bone cancer in children—known as osteosarcoma (OS)— is genetically similar in dogs. The researchers are optimistic that the findings could help break the logjam in the…
Published on July 18, 2019
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark (since acquired by Agilent Technologies) received authorization to market HercepTest. The immunohistochemistry (IHC) assay was designed to detect human epidermal growth factor receptor 2 (HER2) protein…
Published on July 17, 2019
CRISPR-Cas9 is best known for its powerful ability to make double-stranded breaks in DNA, allowing scientists to delete and edit genes with relative ease. But switch out Cas9 for another protein, and CRISPR becomes a programmable tool for detecting the presence of certain nucleic acid sequences. This feature has startups…
Published on July 16, 2019
Medical genetics company Invitae announced that it will acquire Jungla, Inc., a provider of genetic variant clinical interpretation tools in a deal valued at approximately $50 million—comprising $35 million in Invitae stock and $15 million in cash. The deal will strengthen Invitae’s existing suite of genetic variant interpretation with the addition…
Published on July 16, 2019
The way ASCO started for me this year set the scene for what was an inspiring and fascinating weekend. Early on Friday morning, before most people’s ASCOs had started, I sat in a meeting room in the conference center watching it slowly fill to the brim with people. I was…
Published on July 15, 2019
David FitzPatrick’s typical patient is a toddler with global developmental delay who is small for her age, has epilepsy, and cannot speak or understand speech. Often there is no family history of similar symptoms and the parents will report no problems with the pregnancy and birth. The child will have…
Published on July 3, 2019
The FDA has approved an expanded indication for Foundation Medicine’s FoundationOne®CDx, authorizing the test as a companion diagnostic for the AstraZeneca/Merck & Co. co-developed Lynparza (olaparib) for first line maintenance therapy in BRCA-mutated advanced ovarian cancer. FoundationOne CDx is an FDA-approved comprehensive genomic profiling (CGP) test for all solid tumors…
Published on June 12, 2019
By Cindy Perettie, CEO, Foundation Medicine The way ASCO started for me this year set the scene for what was an inspiring and fascinating weekend. Early on Friday morning, before most people’s ASCOs had started, I sat in a meeting room in the conference center watching it slowly fill to…